Elo Mutual Pension Insurance Co Raises Stake in Zimmer Biomet Holdings, Inc. $ZBH

Elo Mutual Pension Insurance Co increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 27.8% in the third quarter, Holdings Channel reports. The firm owned 30,026 shares of the medical equipment provider’s stock after acquiring an additional 6,534 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Zimmer Biomet were worth $2,958,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after buying an additional 198,370 shares during the period. Dodge & Cox raised its stake in shares of Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after acquiring an additional 2,533,009 shares during the period. American Century Companies Inc. lifted its holdings in shares of Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after acquiring an additional 458,903 shares in the last quarter. Geode Capital Management LLC boosted its position in Zimmer Biomet by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after purchasing an additional 69,485 shares during the period. Finally, Primecap Management Co. CA increased its holdings in Zimmer Biomet by 0.6% in the 2nd quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after purchasing an additional 27,860 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $97.99 on Wednesday. The stock has a market capitalization of $19.17 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 2.03 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The company’s 50-day simple moving average is $91.89 and its 200-day simple moving average is $95.81. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same period in the previous year, the company earned $2.31 earnings per share. Zimmer Biomet’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZBH. The Goldman Sachs Group cut Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Friday, January 9th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Finally, Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.